Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort

(2017) Tanya Simuni et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls

(2017) Brit Mollenhauer et al.   NEUROLOGY

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease

(2017) Chelsea Caspell-Garcia et al.   PLoS One

Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan)

(2014) D. G. Grosset et al.   JOURNAL OF NUCLEAR MEDICINE

A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease

(2014) et al.   JAMA Neurology

Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease

(2013) Jeffrey H. Kordower et al.   BRAIN

Calibration of unified Parkinson's disease rating scale scores toMovementDisorder Society-unified Parkinson's disease rating scale scores

(2012) Christopher G. Goetz et al.   MOVEMENT DISORDERS

The Parkinson Progression Marker Initiative (PPMI)

(2011) Kenneth Marek et al.   PROGRESS IN NEUROBIOLOGY

Systematic review of levodopa dose equivalency reporting in Parkinson's disease

(2010) Claire L. Tomlinson et al.   MOVEMENT DISORDERS

Determinants of the Timing of Symptomatic Treatment in Early Parkinson Disease

(2009) Sotirios A. Parashos   ARCHIVES OF NEUROLOGY

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

(2009) C. Warren Olanow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS